Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 5, 2026, 1:38 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 87 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Surfactant Clear all
Completed Not applicable Interventional Accepts healthy volunteers Results available

Effect of Surfactants on the Skin Microbiome

NCT01951391
View directory record Official record
Conditions
Healthy Skin
Interventions
Control Hand Soap, Benzalkonium Chloride Soap, Triclocarban Soap
Other
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 60 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Dec 3, 2019 · Synced Sep 5, 2026, 1:38 PM EDT
Completed Not applicable Interventional

Early Caffeine and LISA Compared to Caffeine and CPAP in Preterm Infants

NCT04209946
View directory record Official record
Conditions
Premature Lungs, Respiratory Distress Syndrome, Surfactant Deficiency Syndrome Neonatal
Interventions
Less Invasive Surfactant Administration LISA, Continuous Positive Airway Pressure CPAP
Procedure
Lead sponsor
Sharp HealthCare
Other
Eligibility
24 Weeks to 29 Weeks
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
3
States / cities
Irvine, California • Loma Linda, California • San Diego, California
Source: ClinicalTrials.gov public record
Updated Dec 17, 2025 · Synced Sep 5, 2026, 1:38 PM EDT
Available No phase listed Expanded access

Molgramostim Nebulizer Solution Expanded Access Program Protocol

NCT06546098
View directory record Official record
Conditions
Autoimmune Pulmonary Alveolar Proteinosis
Interventions
Molgramostim nebulizer solution
Drug
Lead sponsor
Savara Inc.
Industry
Eligibility
18 Years and older
U.S. locations
9
States / cities
Los Angeles, California • Gainesville, Florida • Baltimore, Maryland + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 27, 2026 · Synced Sep 5, 2026, 1:38 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A Single-Center, Exploratory Study to Analyze the Dynamics of Skin Microflora Following Exposure to Surfactants

NCT02615912
View directory record Official record
Conditions
Dermatitis
Interventions
PEG-40 Hydrogenated Castor Oil (Tagat CH40, Evonik) 1.5%, Lauryl glucoside (Plantacare® 1200UP, BASF) 1.5%, Sorbitan palmitate (SPANTM 40 (powder), Croda) 1.5%, Silwet* DA-63 (Momentive) 1.5%, Sodium lauryl sulfate (Sigma Aldrich) 1.0%, Water (control)
Other
Lead sponsor
Kimberly-Clark Corporation
Industry
Eligibility
18 Years to 60 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Irving, Texas
Source: ClinicalTrials.gov public record
Updated Sep 27, 2016 · Synced Sep 5, 2026, 1:38 PM EDT
Completed Phase 2 Interventional

A Safety and Efficacy Study of 552-02 in Subjects With Dry Mouth Associated With Sjogren's Syndrome

NCT00852839
View directory record Official record
Conditions
Dry Mouth Associated With Sjogren's Syndrome, Xerostomia
Interventions
Placebo, 552-02
Drug
Lead sponsor
Parion Sciences
Industry
Eligibility
18 Years to 80 Years
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
15
States / cities
Trumbull, Connecticut • Gainesville, Florida • Indianapolis, Indiana + 12 more
Source: ClinicalTrials.gov public record
Updated Sep 17, 2018 · Synced Sep 5, 2026, 1:38 PM EDT
Terminated Phase 3 Interventional

Early Surfactant to Reduce Use of Mechanical Breathing in Low Birth Weight Infants

NCT00005774
View directory record Official record
Conditions
Infant, Newborn, Respiratory Distress Syndrome, Respiratory Insufficiency
Interventions
Early surfactant, Standard practice
Drug
Lead sponsor
NICHD Neonatal Research Network
Network
Eligibility
Up to 12 Hours
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2002
U.S. locations
13
States / cities
Birmingham, Alabama • Palo Alto, California • New Haven, Connecticut + 10 more
Source: ClinicalTrials.gov public record
Updated Jun 7, 2015 · Synced Sep 5, 2026, 1:38 PM EDT
Recruiting Not applicable Interventional

A Comparative Analysis of REVOLVE, LipoGrafter, and Viality in Autologous Fat Grafting During Breast Surgery

NCT04891510
View directory record Official record
Conditions
Mastectomy, Mammaplasty, Breast Reconstruction
Interventions
REVOLVE Advanced Adipose System, LipoGrafter, Viality
Device · Procedure
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older · Female only
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 21, 2026 · Synced Sep 5, 2026, 1:38 PM EDT
Not listed Phase 4 Interventional

Intra-tracheal Instillation of Budesonide to Prevent Chronic Lung Disease

NCT05364385
View directory record Official record
Conditions
Infant, Extremely Premature, Acute Lung Injury, Chronic Lung Disease of Prematurity, Budesonide
Interventions
Infants in the study group (S/B group) will receive surfactant 2.5 mls/kg and Budesonide 0.5 mg (1mL), Infants in the control group (S/P group) receive placebo (Normal saline 1mL)
Drug
Lead sponsor
University of Arizona
Other
Eligibility
Up to 18 Hours
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Oct 31, 2022 · Synced Sep 5, 2026, 1:38 PM EDT
Completed No phase listed Observational

The Longitudinal Evaluation of Autoimmune Pulmonary Alveolar Proteinosis

NCT03531996
View directory record Official record
Conditions
Autoimmune Pulmonary Alveolar Proteinosis
Interventions
Not listed
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
Not listed
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 23, 2021 · Synced Sep 5, 2026, 1:38 PM EDT
Suspended Phase 2 Interventional

Administration of Surfactant Through an Instillation Device Infasurf® (Calfactant) in Neonates- A Pilot Study

NCT04056741
View directory record Official record
Conditions
RDS of Prematurity, Surfactant Protein B Deficiency, Chronic Lung Disease
Interventions
surfactant airway device
Combination Product
Lead sponsor
ONY
Industry
Eligibility
24 Weeks and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
4
States / cities
San Diego, California • St. Petersburg, Florida • Buffalo, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 31, 2023 · Synced Sep 5, 2026, 1:38 PM EDT
Completed Phase 4 Interventional Results available

Randomized Controlled Trial of Surfactant Delivery Via Laryngeal Mask Airway (LMA) Versus Endotracheal Intubation

NCT01042600
View directory record Official record
Conditions
Respiratory Distress Syndrome, Newborn
Interventions
Endotracheal tube insertion, Laryngeal mask airway insertion
Device
Lead sponsor
Albany Medical College
Other
Eligibility
4 Hours to 48 Hours
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Albany, New York
Source: ClinicalTrials.gov public record
Updated Jul 25, 2019 · Synced Sep 5, 2026, 1:38 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Flublok or Fluzone With Advax-CpG55.2 or AF03

NCT03945825
View directory record Official record
Conditions
Influenza, Influenza Immunisation
Interventions
AF03, Delta Inulin-CpG55.2, Influenza Virus Quadrivalent Inactivated Vaccine, Quadrivalent Recombinant Seasonal Influenza Vaccine
Drug · Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years
Enrollment
241 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
8
States / cities
Atlanta, Georgia • Iowa City, Iowa • Baltimore, Maryland + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2025 · Synced Sep 5, 2026, 1:38 PM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

The Effect of Surfactants on the Bacterial Composition of the Layers of the Skin

NCT02057055
View directory record Official record
Conditions
Focus: Healthy Skin Microbiome
Interventions
Soap 300000027003, Soap 300000029240
Other
Lead sponsor
University of California, San Diego
Other
Eligibility
21 Years to 35 Years · Male only
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Aug 21, 2018 · Synced Sep 5, 2026, 1:38 PM EDT
Completed No phase listed Interventional Accepts healthy volunteers Results available

A Clinical Study to Evaluate Effects of an Oral Rinse on Plaque and Gingivitis

NCT03421145
View directory record Official record
Conditions
Plaque
Interventions
3M™ Oral Rinse, Vehicle Control Oral Rinse, PerioShield™ Oral Health Rinse, Water
Device · Other
Lead sponsor
Solventum US LLC
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Loma Linda, California
Source: ClinicalTrials.gov public record
Updated Sep 30, 2024 · Synced Sep 5, 2026, 1:38 PM EDT
Terminated Phase 1 Interventional

Infasurf®(Calfactant) Aerosol for Infants With Bronchiolitis-AERO-04

NCT03748173
View directory record Official record
Conditions
Bronchiolitis
Interventions
Aerosolized Infasurf
Combination Product
Lead sponsor
ONY
Industry
Eligibility
0 Months to 4 Months
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Oct 22, 2020 · Synced Sep 5, 2026, 1:38 PM EDT
Completed Phase 3 Interventional Results available

Comparison of Aerosol Delivery of Infasurf to Usual Care in Spontaneously Breathing RDS Patients

NCT03058666
View directory record Official record
Conditions
Respiratory Distress Syndrome
Interventions
Aerosolized Calfactant, Solarys
Drug · Device
Lead sponsor
ONY
Industry
Eligibility
1 Hour to 24 Hours
Enrollment
477 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
22
States / cities
Mobile, Alabama • Phoenix, Arizona • San Diego, California + 19 more
Source: ClinicalTrials.gov public record
Updated May 28, 2024 · Synced Sep 5, 2026, 1:38 PM EDT
Terminated Phase 3 Interventional Results available

Phase III Randomized Study of Lucinactant in Full Term Newborn Infants With Meconium Aspiration Syndrome

NCT00004500
View directory record Official record
Conditions
Meconium Aspiration
Interventions
Lucinactant, Standard Care
Drug · Other
Lead sponsor
Windtree Therapeutics
Industry
Eligibility
Up to 48 Hours
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2004
U.S. locations
1
States / cities
Warrington, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 2, 2012 · Synced Sep 5, 2026, 1:38 PM EDT
Completed Phase 1Phase 2 Interventional

Safety, Pk and Anti-inflammatory Effects of CC10 Protein in Premature Infants With Respiratory Distress Syndrome (RDS)

NCT01473264
View directory record Official record
Conditions
Respiratory Distress Syndrome in Premature Infant, Bronchopulmonary Dysplasia
Interventions
recombinant human CC10 (rhCC10), placebo
Drug
Lead sponsor
Clarassance, Inc.
Industry
Eligibility
24 Weeks to 29 Weeks
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2003
U.S. locations
4
States / cities
Wilmington, Delaware • Baltimore, Maryland • Mineola, New York
Source: ClinicalTrials.gov public record
Updated Nov 16, 2011 · Synced Sep 5, 2026, 1:38 PM EDT
Recruiting Not applicable Interventional

Echography-guided Surfactant THERapy (ESTHER) For Preterm Infants With Respiratory Failure

NCT06446453
View directory record Official record
Conditions
Respiratory Distress Syndrome, Newborn, Pulmonary Surfactants, Intensive Care Units, Neonatal
Interventions
Echography-guided Surfactant THERapy (ESTHER)
Diagnostic Test
Lead sponsor
Connecticut Children's Medical Center
Other
Eligibility
0 Hours to 2 Hours
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Hartford, Connecticut
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Sep 5, 2026, 1:38 PM EDT
Recruiting Phase 3 Interventional

Safety and Efficacy of APC-0101 in Preterm Infants With Respiratory Distress Syndrome

NCT06776783
View directory record Official record
Conditions
Respiratory Distress Syndrome, Pre-term Infants
Interventions
APC-0101 (SF-RI 1 surfactant for inhalation combined with a dedicated delivery system), Control
Combination Product · Other
Lead sponsor
Aerogen Pharma Limited
Industry
Eligibility
1 Hour to 24 Hours
Enrollment
520 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
12
States / cities
Little Rock, Arkansas • La Jolla, California • Jacksonville, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Aug 5, 2026 · Synced Sep 5, 2026, 1:38 PM EDT
Active, not recruiting Phase 3 Interventional Results available

The Budesonide in Babies (BiB) Trial

NCT04545866
View directory record Official record
Conditions
Bronchopulmonary Dysplasia (BPD), Respiratory Distress Syndrome, Prematurity; Extreme, Neonatal
Interventions
budesonide (Pulmicort nebulizing suspension)., surfactant (poractant alfa;Curosurf)
Drug
Lead sponsor
NICHD Neonatal Research Network
Network
Eligibility
Up to 48 Hours
Enrollment
642 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
19
States / cities
Birmingham, Alabama • Palo Alto, California • San Diego, California + 15 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2026 · Synced Sep 5, 2026, 1:38 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Steroids and Surfactant in Extremely Low Gestation Age Infants Dose Escalation Trial

NCT02907593
View directory record Official record
Conditions
Bronchopulmonary Dysplasia (BPD)
Interventions
Budesonide in Calfactant
Drug
Lead sponsor
Cynthia McEvoy
Other
Eligibility
3 Days to 14 Days
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
5
States / cities
San Francisco, California • Jacksonville, Florida • Orlando, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 3, 2025 · Synced Sep 5, 2026, 1:38 PM EDT
Terminated Phase 2 Interventional Results available

Poractant Alfa (Curosurf®)) -- Effect in Adult Patients Diagnosed With 2019 Novel Coronavirus (SARS-COV-19; (Covid-19)) Acute Respiratory Distress Syndrome (ARDS)

NCT04502433
View directory record Official record
Conditions
Acute Respiratory Distress Syndrome
Interventions
CUROSURF® (poractant alfa)
Drug
Lead sponsor
Chiesi Farmaceutici S.p.A.
Industry
Eligibility
18 Years to 80 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 22, 2023 · Synced Sep 5, 2026, 1:38 PM EDT
Completed Not applicable Interventional Results available

Self-dispersing Liquids as Aerosol Drug Carriers

NCT00628134
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
calfactant, isotonic saline
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 23, 2017 · Synced Sep 5, 2026, 1:38 PM EDT